NVDA vs PTRN

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.

PTRN presents a stark contrast between strong growth metrics and poor operational health, as evidenced by a weak Piotroski F-Score of 2/9. While the company exhibits impressive YoY revenue growth of 40.30% and a reasonable Forward P/E of 23.01, its net profit margins are razor-thin at 0.65%. The balance sheet is clean with very low debt (D/E 0.05) and strong liquidity (Current Ratio 2.34), but the lack of operational efficiency drags down the deterministic health scores. The stock is currently viewed as a speculative growth play with a significant gap between its current price and analyst targets.